...
首页> 外文期刊>Clinical investigation >Experience in international clinical research: the HIV Prevention Trials Network
【24h】

Experience in international clinical research: the HIV Prevention Trials Network

机译:国际临床研究经验:HIV预防试验网络

获取原文
获取原文并翻译 | 示例

摘要

The HIV Prevention Trials Network (HPTN) is supported by the NIH to conduct randomized clinical trials to assess the efficacy of HIV prevention strategies and technologies to reduce HIV transmission between adults. A special focus of attention is on the use of antiretroviral drugs to prevent HIV transmission, both by reducing infectiousness among HIV-infected persons taking combination antiretroviral therapy (cART) and also by reducing susceptibility among HIV-infected persons taking antiretrovirals for pre-exposure prophylaxis. Studies may be developmental in nature to assess novel ideas for interventions or for assessing trial feasibility. However, pivotal efficacy trials to test HIV-specific prevention strategies and technologies are the main HPTN priority. Examples include a major protocol investigating the impact of expanded testing and linkage to care on HIV surveillance indicators in the USA (HPTN 065). Another protocol is addressing similar issues while also investigating how combinations of prevention approaches are best deployed to make a community-level impact in southern Africa (HPTN 071). HPTN 068 is evaluating a novel conditional cash transfer structural intervention to increase school completion rates in young girls and thereby reduce their HIV risk. Studies outside the US address the epidemic in most at-risk populations and include an assessment of opiate agonist therapy to reduce risk of HIV seroconversion among injection drug users (HTPN 058), methods to increase HIV testing rates (HTPN 043), as well as methods for reducing high-risk behaviors, and increasing adherence to cART in HIV-infected individuals (HPTN 062 and HPTN 063, respectively). The recent HPTN 052 study demonstrated that a 96% reduction in HIV transmission could be achieved between serodiscordant sexual partners by providing the infected partners with cART at a CD4+ cell count (350-550/ul) above the level that would usually qualify them for therapy in low- and middle-income countr...
机译:NIH支持HIV预防试验网络(HPTN)进行随机临床试验,以评估减少成人之间HIV传播的HIV预防策略和技术的有效性。特别关注的焦点是使用抗逆转录病毒药物来预防HIV传播,这既可以通过降低接受联合抗逆转录病毒疗法(cART)的HIV感染者之间的传染性,也可以通过降低接受抗逆转录病毒剂来进行暴露前预防的HIV感染者的易感性来实现。研究本质上可能是发展性的,可以评估用于干预措施或评估试验可行性的新颖思想。然而,HPTN的主要优先重点是测试针对HIV的预防策略和技术的关键功效试验。示例包括一项主要协议,该协议研究了扩大的检测和与护理的联系对美国的HIV监测指标的影响(HPTN 065)。另一个协议正在解决类似问题,同时还研究了如何最好地采用预防方法的组合以在南部非洲对社区产生影响(HPTN 071)。 HPTN 068正在评估一种新颖的有条件现金转移结构干预措施,以提高年轻女孩的学业完成率,从而降低其艾滋病毒风险。美国以外的研究针对大多数高危人群的流行病进行了研究,包括评估鸦片激动剂治疗以减少注射吸毒者中HIV血清转化的风险(HTPN 058),提高HIV检测率的方法(HTPN 043)以及减少高风险行为并增加HIV感染者对cART依从性的方法(分别为HPTN 062和HPTN 063)。最近的HPTN 052研究表明,通过向感染性伴侣提供cART的CD4 +细胞数(350-550 / ul)高于通常使他们有资格接受治疗的水平,可以使血清恶性性伴侣之间的HIV传播减少96%在中低收入国家...

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号